April 25, 2017 3:33 AM ET

Life Sciences Tools and Services

Company Overview of Aphios Corporation

Company Overview

Aphios Corporation develops enabling biotechnology and nanotechnology drug delivery platforms. It also manufactures quality-of-life medicines for health maintenance; research chemicals for standards; and active pharmaceutical ingredients for pharmaceuticals. The company’s therapeutic products include Zindol, an enhanced ginger product; APH-0703, a potent protein kinase C (PKC) activator; APH-0812, a combination therapy consisting of PKC modulators with or without HDAC inhibitors; AMPI-109, a nontoxic Vitamin D3 derivative for hormone refractory prostate cancer; APH-0911, a nanotechnology formulation of Taxotere prodrug with sugar side chain that improves the oral bioavailability of water-sol...

3-E Gill Street

New Boston Park

Woburn, MA 01801

United States

Founded in 1993





Key Executives for Aphios Corporation

Founder, Chairman of The Board, Chief Executive Officer and President
Chief Financial Officer
Compensation as of Fiscal Year 2016.

Aphios Corporation Key Developments

Aphios Pharma Presents at The NYC Family Office & Wealth Management Meeting, Mar-28-2017 11:55 AM

Aphios Pharma Presents at The NYC Family Office & Wealth Management Meeting, Mar-28-2017 11:55 AM. Venue: Pepper Hamilton LLp, New York, New York, United States. Speakers: Karina D. Allen-Ludwig, Scientist.

Aphios Pharma to Develop FDA-Approved, Cannabis-Based Drugs for Opioid Addiction, Epilepsy and Multiple Sclerosis

Aphios Corporation announced that it is spinning-off Aphios® Pharma to develop FDA-approved, cannabis-based drugs for treating highly unmet Central Nervous System (CNS) disorders such as opioid addiction, epilepsy including childhood epilepsy and multiple sclerosis that are only partially and anecdotally addressed by medical marijuana. Opioid addiction has grown to epidemic proportions. Current statistics indicate that heroin overdoses have more than tripled over the last four years. Between 26.4 million and 36 million people abuse opioids worldwide with an estimated 2.1 million people in the US reporting substance abuse disorders related to prescription opioid pain relievers with an estimated 467,000 addicted to heroin. Apart from the enormous burdens on the individuals, families and communities, the US economic burden is significant amounting to an estimated $78 billion annually. However, there is insufficient rigorous clinical evidence of the efficacy of cannabinoids for opioid addiction and other significant CNS disorders, and a lack of availability of pharmaceutical-grade cannabinoids to conduct rigorous clinical trials. These studies must also be conducted in the strict regulatory environments of both the Drug Enforcement Agency (DEA) and the Food and Drug Administration (FDA).

Aphios Corporation Presents at 2016 BIO Investor Forum, Oct-18-2016 09:30 AM

Aphios Corporation Presents at 2016 BIO Investor Forum, Oct-18-2016 09:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Aphios Corporation, please visit www.aphios.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.